Led by researchers at RCSI (Royal College of Surgeons in Ireland), a team of researchers has developed a new treatment for tuberculosis (TB). This work could offer a practical treatment that has the potential to be scaled-up and mass-produced for clinical testing.
The treatment, which patients will take using an inhaler, works by reducing the bacteria in the lungs that causes tuberculosis while also helping the patient’s immune system fight the disease.
There is only one vaccine for tuberculosis, developed in 1921. It is unreliable in preventing the most common form of TB, and is not suitable in all patient groups. The vaccine works best against specific forms of TB and is usually given to infants in at-risk populations.
Tuberculosis is one of the top 10 causes of death worldwide. The World Health Organization (WHO) data show that 10 million people fell ill with TB and 1.6 million died from the disease in 2017. WHO estimates that there were 558,000 new cases with resistance to the most effective first-line antibiotic. Of those resistant to the drug, 82% were resistant to multiple antibiotics.
Funded by the Health Research Board (HRB) and the Royal City of Dublin Hospital Trust, the research is published in the European Journal of Pharmaceutics & Biopharmaceutics.
The work, led by Dr Gemma O’Connor and Prof Sally-Ann Cryan in RCSI, was carried out in collaboration with research teams in St James Hospital, Trinity College Dublin and Imperial College London. Prof Joseph Keane and Dr Mary O’Sullivan led the team at St James Hospital and Trinity College Dublin with Dr Brian Robertson and Dr Nitya Krishnan leading the team at Imperial College London.
Multidrug-resistant TB (MDR-TB) is seen as both a public health crisis and a health security threat. Ending the TB epidemic by 2030 is listed among the health targets of the United Nations Sustainable Development Goals.
The pathogen that causes tuberculosis spreads by people breathing infected droplets into their lungs, where the disease can remain dormant or spread further. The research makes use of a derivative of Vitamin A called all trans retinoic acid, atRA, which previous studies have shown is an effective treatment for tuberculosis.
“Many cases of TB are now becoming resistant to existing antibiotics. This new treatment could be used alongside antibiotics to treat drug-resistant TB and also possibly reduce the rate of antibiotic resistance resulting from conventional antibiotic treatments,” said Prof Cryan, Associate Professor of Pharmaceutics in RCSI School of Pharmacy and the study’s senior author.
Using a spray-drying process, the researchers packaged atRA within safe-for-consumption particles that are small enough to use in an inhaler. These particles efficiently delivered the treatment and significantly reduced tuberculosis-causing bacteria and associated lung damage, which supports their potential for clinical testing.
“Unfortunately, tuberculosis remains a significant problem for world health. We urgently need innovative treatments like this one if we are to achieve the UN 2030 health targets,” said Prof Keane, Professor at Trinity College Dublin School of Medicine and Consultant Respiratory Physician in St James’s Hospital.
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- Tuberculosis Found In Pittsburgh Public Schools: Doctors Warn How To Prevent Spreadingon December 11, 2019 at 3:29 pm
PITTSBURGH (KDKA) — A student at Arsenal 6-8 has tuberculosis. This bacterial infection is spread through the air. It can affect any part of the body, but usually the lungs, with a person developing a ...
- How To Keep Tuberculosis From Spreadingon December 11, 2019 at 2:19 pm
After a local student at Arsenal Middle School was diagnosed with tuberculosis, KDKA's Dr. Maria Simbra spoke with other health officials in order to let people know how to keep more people from ...
- Allegheny Co. Health Department confirms active tuberculosis case in student at Pittsburgh schoolon December 11, 2019 at 9:39 am
PITTSBURGH — The Allegheny County Health Department has confirmed an active case of tuberculosis in a student at Pittsburgh Arsenal 6-8 in Lawrenceville. The student is currently not in school and is ...
- Tuberculosis case at Pittsburgh school isn’t cause for panic, says health departmenton December 11, 2019 at 8:51 am
A confirmed case of tuberculosis at Arsenal 6-8 school in Lawrenceville doesn’t pose a risk of the disease spreading through the community, health officials said Wednesday “There is absolutely no ...
- Tuberculosis: New drug substance BTZ-043 is being tested on patients for the first timeon December 11, 2019 at 5:07 am
Since mid-November, the first tuberculosis patients in Cape Town, South Africa, have been treated with the new drug substance BTZ-043 for the first time. The study is carried out within the PanACEA ...
- Student Diagnosed With Tuberculosis At Pittsburgh Arsenal 6-8on December 10, 2019 at 4:21 pm
The Allegheny County Health Department has identified tuberculosis (TB) in a student at Pittsburgh Arsenal 6-8, a Pittsburgh Public School, in Lawrenceville. The student is not currently in school and ...
- Tuberculosis exposure reported at north Iowa school districton December 10, 2019 at 10:58 am
Tuberculosis exposure reported at north Iowa school district Hampton-Dumont Community School District is setting up a clinic for TB testing. About 1,275 students between pre-K and high school attend ...
- Plasma metabolomics in tuberculosis patients with and without concurrent type 2 diabetes at diagnosis and during antibiotic treatmenton December 10, 2019 at 2:22 am
Tuberculosis (TB) and type 2 diabetes mellitus (DM), a major TB risk factor, are both accompanied by marked alterations in metabolic processes. Dissecting the specific metabolic changes induced by ...
- Here is how tuberculosis bacteria evade treatmenton December 9, 2019 at 9:10 pm
Mycobacterium tuberculosis (Mtb) the pathogen responsible for tuberculosis (TB) in humans causes nearly 1.5 million deaths annually across the globe. Researchers from Council of Scientific and ...
- Tuberculosis Testing Market Next Big Thing (2020-2029) | Abbott Laboratories, Akonni Biosystems Inc. and Alere Inc.on December 9, 2019 at 12:46 am
Dec 09, 2019 (WiredRelease via COMTEX) -- Market.us has recently published a comprehensive and exclusionary research report titled, “Tuberculosis Testing Market Trends by Types (Smear Microscopy, ...
via Bing News